Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France (ORCHIDEE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01197183
Recruitment Status : Completed
First Posted : September 9, 2010
Last Update Posted : February 4, 2014
Information provided by:
Merck KGaA

Brief Summary:
This observational survey with prospective and/or retrospective follow-up is designed to study practices for the initial treatment of hypothyroidism in France without modifying subject treatment.

Condition or disease

Detailed Description:

Thyroid disorder can be central, caused by a deficiency in thyroid stimulating hormone (TSH) production; or peripheral, caused by the decrease in the plasma concentration of thyroid hormones, more specifically of free thyroxine (free T4). Peripheral hypothyroidism is caused by the decrease in the production capacities of the thyroid gland.

The treatment of hypothyroidism is based on the restoration and maintenance of biological (judged on the basis of the standardised TSH and T4 values) and clinical euthyroidism.

A number of forms of thyroid hormones are available in the French market (Euthyral®, Cynomel®, L-thyroxine drops®), of which, Levothyrox® is the most frequently prescribed drug in this category.

The treatment of peripheral hypothyroidism, in particular, is well codified and almost consensual. In France, there is no published observational study, based on which one can document the manner in which subjects are treated. This observational study is set up to document these practices.

OBJECTIVES The principal objectives of this survey is to to get information on the use of Levothyrox in France

  • Circumstances of diagnosis
  • Record realised
  • Terms and conditions of treatment by the general practitioner and/or the endocrinologist

The secondary objective is to evaluate the inclusion criteria for levothyroxine treatment.

For each subject the participating doctor will complete a follow up questionnaire form until the first control level of TSH after the diagnosis of hypothyroidism.

Study Type : Observational
Actual Enrollment : 1285 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Survey for the Initial Treatment of Hypothyroidism in France
Study Start Date : October 2008
Actual Primary Completion Date : May 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypothyroidism

Primary Outcome Measures :
  1. Initial questionnaire [ Time Frame: Baseline ]
    Documentation of indications for levothyroxine treatment

Secondary Outcome Measures :
  1. Follow-up questionnaire [ Time Frame: 3 months ]
    Documentaion of inclusion criteria (socio-demographic and clinical data, treatment information and biological values) for levothyroxine treatment. Follow-up questionnaire filled-in until the result of the first TSH level after commencement of therapy with thyroid hormones.

Biospecimen Retention:   Samples With DNA
Whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Independent, hospital and mixed practice endocrinologists and general practitioners enrolled 1000 subjects.

Inclusion Criteria:

  • Recently diagnosed hypothyroid subject (either during the inclusion period, or within the 6 previous months) for whom, data related to the diagnosis is available if the diagnosis was not carried out initially by the investigating doctor
  • Subject, who has given his/her oral consent for participation

Exclusion Criteria:

  • Subject included in clinical trial or having participated in a clinical trial during the last 3 months
  • Subject presenting a major and objectifiable risk of not being able to follow-up until the next TSH level (moving, problems encountered during another study, pathology affecting the vital prognosis in the short-term)
  • All contraindications to Lévothyrox

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01197183

Merck Lipha Santé Laboratories
Saint Romain, Lyon, France, 69008
Sponsors and Collaborators
Merck KGaA
Study Director: Dr. Frederic Landron, MD Laboratoires Merck Lipha Santé

Responsible Party: Dr. Frederic Landron, Laboratoires Merck Lipha Santé, an affiliate of Merck KGaA, Darmstadt, Germany Identifier: NCT01197183     History of Changes
Other Study ID Numbers: 200007-502
First Posted: September 9, 2010    Key Record Dates
Last Update Posted: February 4, 2014
Last Verified: September 2010

Keywords provided by Merck KGaA:
Thyroid hormones

Additional relevant MeSH terms:
Thyroid Diseases
Endocrine System Diseases